StockNews.AI
BIOA
StockNews.AI
197 days

BioAge Labs, Inc. (BIOA) Investors: March 10, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

1. A securities class action lawsuit has been filed against BioAge Labs. 2. Allegations include misleading statements about STRIDES Phase 2 trial results. 3. Investors are encouraged to seek lead plaintiff status by March 10, 2025. 4. Defendants allegedly failed to disclose safety concerns from earlier trials. 5. Misrepresentation may significantly affect BioAge's stock value moving forward.

5m saved
Insight
Article

FAQ

Why Very Bearish?

Legal issues often lead to stock price declines, as seen with companies like Theranos.

How important is it?

Litigation against BIOA directly pertains to its stock and investor trust.

Why Long Term?

Ongoing litigation may result in prolonged negative sentiment towards BIOA.

Related Companies

BIOA
RADNOR, Pa., Feb. 3, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioAge Labs, Inc. ("BioAge") (NASDAQ: BIOA) on behalf of those who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering ("IPO") held on or about September 26, 2024 (the "Class Period"). The lead plaintiff deadline is March 10, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered BioAge losses, you may CLICK HERE or copy and paste the following link in your browser: https://www.ktmc.com/new-cases/bioage-labs-inc?utm_source=PR&utm_medium=link&utm_campaign=bioa&mktm=r You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, in the registration statement and prospectus issued in connection with BioAge's IPO, Defendants made false and/or misleading statements and/or failed to disclose information pertinent to investors concerning BioAge's STRIDES Phase 2 trial for azelaprag. Specifically, Defendants misrepresented and/or failed to disclose: (1) the potential for liver transaminitis in any of its previous clinical STRIDES Phase 1 trials and various preclinical tox studies; (2) that there were no safety concerns and that BioAge expected top line results and to meet its primary endpoint goals in connection with its STRIDES clinical trial; and (3) as a result, Defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. THE LEAD PLAINTIFF PROCESS: BioAge investors may, no later than March 10, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages BioAge investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO:  https://www.ktmc.com/new-cases/bioage-labs-inc?utm_source=PR&utm_medium=link&utm_campaign=bioa&mktm=r ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world.  The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com. CONTACT:Kessler Topaz Meltzer & Check, LLPJonathan Naji, Esq.(484) 270-1453280 King of Prussia RoadRadnor, PA 19087[email protected] May be considered attorney advertising in certain jurisdictions.  Past results do not guarantee future outcomes. SOURCE Kessler Topaz Meltzer & Check, LLP

Related News